BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20732964)

  • 1. Novel models of myxoid liposarcoma xenografts mimicking the biological and pharmacologic features of human tumors.
    Frapolli R; Tamborini E; Virdis E; Bello E; Tarantino E; Marchini S; Grosso F; Sanfilippo R; Gronchi A; Tercero JC; Peloso G; Casali P; Pilotti S; D'Incalci M
    Clin Cancer Res; 2010 Oct; 16(20):4958-67. PubMed ID: 20732964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of action of trabectedin in myxoid liposarcomas.
    Di Giandomenico S; Frapolli R; Bello E; Uboldi S; Licandro SA; Marchini S; Beltrame L; Brich S; Mauro V; Tamborini E; Pilotti S; Casali PG; Grosso F; Sanfilippo R; Gronchi A; Mantovani R; Gatta R; Galmarini CM; Sousa-Faro JM; D'Incalci M
    Oncogene; 2014 Oct; 33(44):5201-10. PubMed ID: 24213580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
    Germano G; Frapolli R; Simone M; Tavecchio M; Erba E; Pesce S; Pasqualini F; Grosso F; Sanfilippo R; Casali PG; Gronchi A; Virdis E; Tarantino E; Pilotti S; Greco A; Nebuloni M; Galmarini CM; Tercero JC; Mantovani A; D'Incalci M; Allavena P
    Cancer Res; 2010 Mar; 70(6):2235-44. PubMed ID: 20215499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
    Grosso F; Jones RL; Demetri GD; Judson IR; Blay JY; Le Cesne A; Sanfilippo R; Casieri P; Collini P; Dileo P; Spreafico C; Stacchiotti S; Tamborini E; Tercero JC; Jimeno J; D'Incalci M; Gronchi A; Fletcher JA; Pilotti S; Casali PG
    Lancet Oncol; 2007 Jul; 8(7):595-602. PubMed ID: 17586092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
    Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DDIT3 gene break-apart as a molecular marker for diagnosis of myxoid liposarcoma--assay validation and clinical experience.
    Narendra S; Valente A; Tull J; Zhang S
    Diagn Mol Pathol; 2011 Dec; 20(4):218-24. PubMed ID: 22089349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systems biology approach to characterize the regulatory networks leading to trabectedin resistance in an in vitro model of myxoid liposarcoma.
    Uboldi S; Calura E; Beltrame L; Fuso Nerini I; Marchini S; Cavalieri D; Erba E; Chiorino G; Ostano P; D'Angelo D; D'Incalci M; Romualdi C
    PLoS One; 2012; 7(4):e35423. PubMed ID: 22523595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues.
    Hisaoka M; Tsuji S; Morimitsu Y; Hashimoto H; Shimajiri S; Komiya S; Ushijima M
    Diagn Mol Pathol; 1998 Apr; 7(2):96-101. PubMed ID: 9785008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PPARĪ³ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.
    Charytonowicz E; Terry M; Coakley K; Telis L; Remotti F; Cordon-Cardo C; Taub RN; Matushansky I
    J Clin Invest; 2012 Mar; 122(3):886-98. PubMed ID: 22293175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric TLS/FUS-CHOP gene expression and the heterogeneity of its junction in human myxoid and round cell liposarcoma.
    Kuroda M; Ishida T; Horiuchi H; Kida N; Uozaki H; Takeuchi H; Tsuji K; Imamura T; Mori S; Machinami R
    Am J Pathol; 1995 Nov; 147(5):1221-7. PubMed ID: 7485386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.
    Forni C; Minuzzo M; Virdis E; Tamborini E; Simone M; Tavecchio M; Erba E; Grosso F; Gronchi A; Aman P; Casali P; D'Incalci M; Pilotti S; Mantovani R
    Mol Cancer Ther; 2009 Feb; 8(2):449-57. PubMed ID: 19190116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUS/TLS-CHOP chimeric transcripts in liposarcoma tissues.
    Yang X; Nagasaki K; Egawa S; Maruyama K; Futami H; Tsukada T; Yokoyama R; Beppu Y; Fukuma H; Shimoda T
    Jpn J Clin Oncol; 1995 Dec; 25(6):234-9. PubMed ID: 8523819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic activity of trabectedin in myxoid liposarcoma: involvement of host TIMP-1 and TIMP-2 and tumor thrombospondin-1.
    Dossi R; Frapolli R; Di Giandomenico S; Paracchini L; Bozzi F; Brich S; Castiglioni V; Borsotti P; Belotti D; Uboldi S; Sanfilippo R; Erba E; Giavazzi R; Marchini S; Pilotti S; D'Incalci M; Taraboletti G
    Int J Cancer; 2015 Feb; 136(3):721-9. PubMed ID: 24917554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.
    D'Incalci M; Badri N; Galmarini CM; Allavena P
    Br J Cancer; 2014 Aug; 111(4):646-50. PubMed ID: 24755886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
    Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
    Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.
    Antonescu CR; Tschernyavsky SJ; Decuseara R; Leung DH; Woodruff JM; Brennan MF; Bridge JA; Neff JR; Goldblum JR; Ladanyi M
    Clin Cancer Res; 2001 Dec; 7(12):3977-87. PubMed ID: 11751490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel type of EWS-CHOP fusion gene in myxoid liposarcoma.
    Matsui Y; Ueda T; Kubo T; Hasegawa T; Tomita Y; Okamoto M; Myoui A; Kakunaga S; Yasui N; Yoshikawa H
    Biochem Biophys Res Commun; 2006 Sep; 348(2):437-40. PubMed ID: 16884691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The intriguing patterns of tumor response to trabectedin.
    Sanfilippo R; Casali PG
    Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):21-4. PubMed ID: 23638727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas.
    Hisaoka M; Morimitsu Y; Hashimoto H; Ishida T; Mukai H; Satoh H; Motoi T; Machinami R
    Am J Surg Pathol; 1999 Dec; 23(12):1480-92. PubMed ID: 10584701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comprehensive review of the current evidence for trabectedin in advanced myxoid liposarcoma.
    Assi T; Kattan J; El Rassy E; Honore C; Dumont S; Mir O; Le Cesne A
    Cancer Treat Rev; 2019 Jan; 72():37-44. PubMed ID: 30468937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.